France· FR:63648081
ENHERTU 100 mg, poudre pour solution à diluer pour perfusion
A medicinal product containing trastuzumab déruxtécan, registered in France by DAIICHI SANKYO EUROPE (ALLEMAGNE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- TRASTUZUMAB DÉRUXTÉCAN
- Manufacturer
- DAIICHI SANKYO EUROPE (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550792931 flacon(s) en verre jaune(brun) de 10 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Trastuzumab déruxtécan in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsEnhertu 100 mg, poeder voor concentraat voor oplossing voor infusieDAIICHI SANKYO EUROPE GmbH
- SpainENHERTU 100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONDaiichi Sankyo Europe Gmbh
- FinlandEnhertuAbacus Medicine A/S
- SwitzerlandEnhertu
- CzechiaENHERTUDaiichi Sankyo Europe GmbH, Mnichov
- United KingdomEnhertu 100mg powder for concentrate for solution for infusion vialsDaiichi Sankyo UK Ltd
- IrelandEnhertu 100 mg powder for concentrate for solution for infusionDaiichi Sankyo Europe GmbH
- IcelandEnhertuDAIICHI SANKYO EUROPE GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Enhertu
- Liechtenstein · Enhertu
- Norway · Enhertu
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7b89c0a2-4851-4c3a-81b7-e5fbffbbcbbb GET /v1/drugs/7b89c0a2-4851-4c3a-81b7-e5fbffbbcbbb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "63648081",
"date_amm": "2021-01-18",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1508",
"substance": "TRASTUZUMAB DÉRUXTÉCAN",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "poudre pour solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about trastuzumab déruxtécan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.